Evidence map›Paper›PMID 42723250›Full record

ArticleChembiochem : a European journal of chemical biology2026

N8-Modified Quino[4,3,2-Kl]acridines as Promising Antimalarial G-Quadruplex Ligands.

Steve Saulnier, Marco Antônio G B Gomes, Mariam Salim, Maxime Guichonnet, Michel Nguyen, Laure Vendier, Flore Nardella, Jean-Michel Augereau, Dennis Gomez, Anne Robert and 1 more

Abstract read
In one paragraph

Article in Chembiochem : a European journal of chemical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. N8-Modified Quino[4,3,2-Kl]acridines as Promising Antimalarial G-Quadruplex Ligands.Chembiochem : a European journal of chemical biology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Steve SaulnierLaboratoire de Chimie de Coordination du CNRS (LCC-CNRS), Inserm ERL 1289 MAAP, Université de Toulouse, Toulouse, France.
Marco Antônio G B GomesLaboratoire de Chimie de Coordination du CNRS (LCC-CNRS), Inserm ERL 1289 MAAP, Université de Toulouse, Toulouse, France.
Mariam SalimLaboratoire de Chimie de Coordination du CNRS (LCC-CNRS), Inserm ERL 1289 MAAP, Université de Toulouse, Toulouse, France.
Maxime GuichonnetLaboratoire de Chimie de Coordination du CNRS (LCC-CNRS), Inserm ERL 1289 MAAP, Université de Toulouse, Toulouse, France.ORCID https://orcid.org/0009-0006-7340-0517
Michel NguyenLaboratoire de Chimie de Coordination du CNRS (LCC-CNRS), Inserm ERL 1289 MAAP, Université de Toulouse, Toulouse, France.ORCID https://orcid.org/0000-0002-6496-0495
Laure VendierLaboratoire de Chimie de Coordination du CNRS (LCC-CNRS), Inserm ERL 1289 MAAP, Université de Toulouse, Toulouse, France.ORCID https://orcid.org/0000-0002-7111-9258
Flore NardellaLaboratoire de Chimie de Coordination du CNRS (LCC-CNRS), Inserm ERL 1289 MAAP, Université de Toulouse, Toulouse, France.ORCID https://orcid.org/0000-0002-3811-1633
Jean-Michel AugereauLaboratoire de Chimie de Coordination du CNRS (LCC-CNRS), Inserm ERL 1289 MAAP, Université de Toulouse, Toulouse, France.ORCID https://orcid.org/0000-0002-2847-1969
Dennis GomezInstitut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, Toulouse, France.ORCID https://orcid.org/0000-0001-9942-1451
Anne RobertLaboratoire de Chimie de Coordination du CNRS (LCC-CNRS), Inserm ERL 1289 MAAP, Université de Toulouse, Toulouse, France.ORCID https://orcid.org/0000-0002-9092-6776
Françoise Benoit-VicalLaboratoire de Chimie de Coordination du CNRS (LCC-CNRS), Inserm ERL 1289 MAAP, Université de Toulouse, Toulouse, France.ORCID https://orcid.org/0000-0002-9468-4823

Funding

Agence nationale de la Recherche ANR-22-CE18-0005Centre National de la Recherche Scientifique (CNRS)Fondation pour la recherche médicale EQU202103012596Institut National de la Santé et de la Recherche Médicale (Inserm)SATT Toulouse Tech Transfer
6 · The paper itself

Abstract

To face the increasing multidrug resistance of the malaria parasite Plasmodium falciparum, the development of new compounds that act in novel ways is urgent. G-quadruplexes (G4), Guanine-rich secondary structures of DNA and RNA sequences, have an essential role in cell survival and cell metabolism regulation, including in Plasmodium. We have recently demonstrated that the G-quadruplex ligand RHPS4, an acridine derivative, displays strong antiplasmodial activity by disrupting P. falciparum through G4 stabilization, leading to parasite death. Based on this original mode of action, we propose here a series of new RHPS4 analogues. These derivatives were then tested against P. falciparum and on human cells to evaluate their selectivity index. They exhibited IC

Indexed as

AcridinesAntimalarialsG-QuadruplexesPlasmodium falciparumQuinolinesHumansLigandsStructure-Activity RelationshipAcridinesAntimalarialsLigandsQuinolinesantimalarial drugG‐quadruplexmedicinal chemistrynitrogen heterocyclesPlasmodium falciparumRHPS4

Identifiers

PMID42723250
PMCPMC13562830

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.